Saturday 17 October 2026
Export MNOV’s income statement to Excel — free account
MediciNova, Inc.
MNOV Healthcare Biotechnology
MediciNova, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $409,700.00, down 59.0% from fiscal 2023. In the quarter to June 2026, revenue grew 240.6%, EPS grew 28.6% and free cash flow grew 16.8%, each against the same quarter a year earlier.
1.42
0.03
−2.07%
Follow MNOV
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | 0.00 | — | 0.00 | — | 0.00 |
Altman Z-Score |
— | — | — | — | — | 15.27 | — | 2.95 | — | (4.10) |
P/S ratio |
— | — | — | — | — | 12.97 | — | 7.33 | — | 45.60 |
P/FCF ratio |
— | — | — | — | — | 0.00 | — | 6.52 | — | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | 13.31 | — | 0.12 | — | (18.54) |
P/Operating CF |
— | — | — | — | — | (35.79) | — | (162.18) | — | (31.87) |
P/B ratio |
— | — | — | — | — | 1.56 | — | 1.30 | — | 1.55 |
Price to Tangible BV |
— | — | — | — | — | 1.76 | — | 1.53 | — | 2.01 |
EV/Sales |
— | — | — | — | — | 5.86 | — | 2.71 | — | 23.74 |
EV/EBITDA |
— | — | — | — | — | 0.00 | — | 0.00 | — | 0.00 |
EV/Operating CF |
— | — | — | — | — | (6.27) | — | (4.03) | — | (3.41) |
EV/FCF |
— | — | — | — | — | (6.23) | — | 2.41 | — | (3.41) |
Quick Ratio |
14.80 | 9.72 | 28.43 | 28.63 | 27.36 | 25.21 | 18.35 | 15.55 | 13.64 | 8.11 |
Current Ratio |
15.15 | 9.83 | 28.63 | 28.86 | 27.67 | 25.42 | 18.51 | 15.61 | 13.88 | 8.16 |
Net Debt/EBITDA |
2.22 | 2.15 | 4.00 | 4.55 | 4.24 | 7.01 | 4.00 | 5.16 | 3.19 | 2.32 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.00 | 0.01 | 0.00 | 0.01 |
Operating CF/Net income |
0.60 | 0.62 | 0.62 | 0.71 | 0.78 | 0.93 | 0.92 | 0.87 | 0.96 | 0.82 |
Capex/Depreciation |
(5.99) | 0.00 | (0.39) | (0.47) | (1.71) | (1.10) | 1,122.74 | (1.05) | (0.03) | (0.14) |
Interest Coverage |
163.39 | 89.53 | (16.58) | (12.22) | (39.25) | (71.14) | (18.07) | — | — | — |
| (32.30%) | (30.51%) | (26.26%) | (17.49%) | (18.95%) | (13.08%) | (18.28%) | (12.93%) | (19.24%) | (25.50%) | |
| (27.96%) | (26.82%) | (24.33%) | (16.55%) | (17.92%) | (12.45%) | (17.42%) | (12.21%) | (18.09%) | (23.65%) | |
ROIC |
(65.31%) | (76.45%) | (90.25%) | (78.99%) | (78.49%) | (52.14%) | (77.78%) | (54.38%) | (65.23%) | (77.01%) |
Return on Tangible Assets |
(46.91%) | (43.76%) | (24.21%) | (20.83%) | (23.65%) | (14.64%) | (25.19%) | (17.88%) | (28.97%) | (44.11%) |
Average Days of Receivables |
— | — | — | — | — | 0.00 | — | 0.00 | — | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 211.47% | 0.00% | 565.79% | 0.00% | 1,746.35% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 141.56% | 0.00% | 524.24% | 0.00% | 1,503.34% |
Intangible Assets out of Total Assets |
0.24 | 0.22 | 0.12 | 0.12 | 0.13 | 0.11 | 0.13 | 0.14 | 0.17 | 0.21 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 42.54% | 0.00% | 71.07% | 0.00% | 202.37% |
Graham Net Nets |
— | — | — | — | — | 0.52 | — | 0.58 | — | 0.42 |
Graham Number |
— | — | — | — | — | 0.00 | — | 0.00 | — | 0.00 |
Earnings Yield |
— | — | — | — | — | (7.75%) | — | (10.59%) | — | (18.32%) |
Free Cash Flow Yield |
— | — | — | — | — | (7.25%) | — | 15.35% | — | (15.27%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.00 | 0.02 | 0.00 | 0.01 |
Operating CF per Share |
(0.20) | (0.20) | (0.22) | (0.21) | (0.24) | (0.19) | (0.26) | (0.15) | (0.22) | (0.20) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.41 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.20) | (0.20) | (0.22) | (0.21) | (0.24) | (0.19) | 0.14 | (0.15) | (0.22) | (0.20) |
Cash per Share |
0.73 | 0.80 | 1.52 | 1.48 | 1.35 | 1.47 | 1.19 | 1.04 | 0.82 | 0.63 |
Shareholders Equity per Share |
1.05 | 1.10 | 1.78 | 1.74 | 1.61 | 1.72 | 1.43 | 1.27 | 1.07 | 0.85 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.05 | 1.10 | 1.78 | 1.74 | 1.61 | 1.72 | 1.43 | 1.27 | 1.07 | 0.85 |
Free Cash Flow |
(6.63) | (6.92) | (9.12) | (9.14) | (10.86) | (9.41) | 6.96 | (7.45) | (10.64) | (9.81) |
Working Capital |
23.07 | 25.45 | 60.57 | 62.08 | 58.52 | 69.18 | 55.80 | 47.90 | 38.12 | 27.19 |
Capital Expenditures |
(0.08) | — | (0.01) | (0.01) | (0.04) | (0.03) | 19.87 | (0.02) | 0.00 | 0.00 |
Net Current Asset Value |
19.42 | 23.55 | 58.64 | 59.99 | 56.62 | 68.28 | 55.07 | 47.28 | 37.70 | 26.97 |
EV/EBIT |
— | — | — | — | — | 0.00 | — | 0.00 | — | 0.00 |
Capex to Sales |
0.00 | — | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.02 | 0.00 | 0.01 |
Price to Operating Income |
— | — | — | — | — | 0.00 | — | 0.00 | — | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.16 | 0.45 | 0.49 | 0.59 | 0.38 | 0.45 | 0.39 | 0.44 | 0.83 | 2.42 |
Cash ROIC |
(11.31%) | (10.39%) | (6.74%) | (6.59%) | (8.27%) | (6.07%) | 5.41% | (6.57%) | (11.46%) | (13.56%) |
Accounts Receivable Turnover |
— | — | — | — | — | 0.00 | — | 0.00 | — | 0.00 |
Accounts Payable Turnover |
0.05 | 0.03 | 0.02 | 0.04 | 0.04 | 0.00 | 0.51 | 0.00 | 0.00 | 0.44 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — | 0.00 |
Average Days of Payables |
9,508.12 | 19,746.37 | 8,692.36 | 6,892.24 | 10,566.15 | 0.00 | 729.66 | 0.00 | 0.00 | 602.55 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — | 0.00 |
Average Payables |
0.27 | 0.94 | 1.07 | 0.53 | 0.53 | 0.51 | 0.41 | 0.71 | 1.05 | 0.86 |
Average Assets |
38.86 | 41.62 | 60.32 | 78.21 | 77.31 | 81.41 | 80.78 | 70.21 | 61.07 | 50.74 |
Average Common Equity |
33.64 | 36.59 | 55.87 | 74.00 | 73.11 | 77.50 | 76.96 | 66.31 | 57.44 | 47.05 |
Columns are period end dates